Share on StockTwits

Ultragenyx Pharmaceutical (NASDAQ:RARE) Director William Aliski purchased 5,000 shares of Ultragenyx Pharmaceutical stock in a transaction dated Thursday, January 30th. The stock was purchased at an average price of $21.00 per share, with a total value of $105,000.00. Following the completion of the transaction, the director now directly owns 36,903 shares of the company’s stock, valued at approximately $774,963. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) traded down 7.69% on Monday, hitting $39.00. 498,216 shares of the company’s stock traded hands. Ultragenyx Pharmaceutical has a one year low of $38.52 and a one year high of $47.99. The stock’s 50-day moving average is $40.6 and its 200-day moving average is $40.6. The company’s market cap is $144.4 million.

Ultragenyx Pharmaceutical Inc is a development-stage biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.